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Introduction:We have created a non-human primate (NHP)
model of GvHD. Here we determined whether mTOR inhi-
bition with sirolimus and CD28:CD80/86 costimulation
blockade with belatacept could combine synergistically to
prevent this disease.
Methods: Rhesus macaques were irradiated (9.6 Gy), and
then transplanted with GCSF-mobilized PBSC from a hap-
loidentical donor. Recipients were treated with either siro-
limus alone, belatacept alone or combination therapy.
Clinical GvHD was monitored using an NHP grading scale
and multiparameter ﬂow cytometric analysis (MFC) was
performed.
Results: Untreated controls (n ¼ 5) developed rapid, severe
aGvHD and succumbed rapidly (MST ¼ 7 days). Treatment
with either sirolimus or belatacept alone partially protected
against GvHD. Sirolimus-treated recipients (n ¼ 6) devel-
oped predominantly GI disease and had an MST of 14 days
(Figure 1A). Recipients treated with belatacept alone (n ¼ 3)
developed primarily liver aGvHD and had an MST of 11 days.
In striking contrast, recipients treated with combined siro-
limus + belatacept (n ¼ 5) demonstrated neither uncon-
trolled diarrhea nor hyperbilirubinemia at the timed
terminal analysis (1 month post-transplant).
We used MFC to measure the immunologic consequences
of sirolimus and belatacept on T cell proliferation (Ki-67) and
cytotoxity (granzyme B). While untreated aGvHD was asso-
ciated with rampant CD8+ proliferation (with 83% Ki-67+
CD8+ T cells vs 4.7% pre-transplant), sirolimus or belatacept
monotherapy partially controlled proliferation (35% and 65%
Ki-67+ with sirolimus or belatacept respectively). Combined
sirolimus + belatacept dramatically reduced proliferation (to
8%, favorably comparing with 13% Ki-67+ using tacrolimus/
MTX).
Sirolimus and belatacept also partially controlled T cell
cytotoxicity: While untreated aGvHD was associated
with excessive CD8+ granzyme B expression (82% granzyme
Bvery high vs 0.3% pre-transplant) sirolimus or belatacept
monotherapy partially controlled cytotoxicity (8% and 35 %
granzyme Bvery high with sirolimus or belatacept respec-
tively). Combination therapy dramatically reduced granzyme
Bvery high expression, to 1.5%, favorably comparing with 4%
using CNI/MTX.
The ability of sirolimus, belatacept, or the combination to
control Ki-67 and Granzyme B expression closely correlated
with survival (Figure 1B,C), and signiﬁcant co-expression of
granzyme B in the Ki-67+ cells was observed (Figure 1D),
suggesting that dual-positive Ki-67/Granzyme B cells may
mark a pathogenic population, amenable to tracking in the
peripheral blood.Implications: These results show, for the ﬁrst time, that
sirolimus and belatacept can combine synergistically to
control primate aGvHD. They also identify CD8+/Ki-67+/
Granzyme Bvery high dual-positive T cells as a potentially
sensitive biomarker of GvHD pathogenesis, amenable to
monitoring longitudinally in the blood.
Figure 1. Synergistic Control of Acute GvHD With Sirolimus + belatacept
(A) Dual therapy with sirolimus + belatacept synergistically prolongs survival
in a NHP aGvHD model.
(B) Proliferation, measured by Ki-67+ CD8+ T cells, correlates with clinical
aGvHD severity.
(C) Cytoxicity, measured by Granzyme B expression in CD8+ T cells, correlates
with clinical aGvHD severity.
(D) Signiﬁcant co-expression of KI-67 and Granzyme B in pathogenic CD8+ T
cells.
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Chronic graft versus host disease (cGvHD) remains
a major complication of allogeneic hematopoietic stem cell
transplantation (HSCT). At present, the immunopathophysi-
ology of cGVHD is not fully understood. A number of pre-
clinical and clinical studies support a role for B cell involve-
ment in the pathogenesis of cGvHD. Increased numbers of
CD21- B cell, believed to be immature/ transitional B cells,
were recently reported in the peripheral blood (PB) of cGvHD
patients. In this study, we report the expansion of a CD21- B
cell populationwith an exhausted phenotype in the memory
B cell compartment of patients with active cGVHD. Using
multicolor ﬂow cytometry we performed an extensive
anaylsis of B phenotype and function in 16 patients with
active cGvHD compared to 14 age-matched HSCT recipients
without clinical evidence of cGVHD and 11 healthy controls.
Chronic GvHD patients had signiﬁcantly higher frequencies
of CD21- B cells in the PB compared with patients without
cGvHD and HC (median 12.2% vs. 2.12% vs. 3%; P < 0.01).
Multi-parameter ﬂow cytometry revealed that the majority
of these cells were CD10- CD27- CD21‑ CD20hi, reminiscent
of the recently described exhausted B cells in HIV
patients with chronic viremia. We did not observe increased
transitional (CD24hi-CD38hi- CD19+) or immature B cells
(CD10+CD21-CD27-CD19+) in cGvHD patients compared with
patients with no cGVHD (median transitional 3.4% vs. 6.3%;
p¼0.08) and (median immature (out of total CD21- B cells)
